Elżbieta J.
- Country
- Poland
- Department
- n/a
Research Overview
- A Phase 3b Study Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Antiretroviral-Naive Adults with HIV
- Evaluation of the Efficacy and Safety of GS-1720 and GS-4182 Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Patients
- Randomized, Active-Controlled Phase 2/3 Study of GS-1720 and GS-4182 Versus Biktarvy in Treatment-Naive HIV-1 Patients
Data & Insights
Has run more than one trial at 16 of 80 partner sites.
Specializations
HIV Treatment Innovation
This investigator specializes in advancing therapeutic approaches for Human Immunodeficiency Virus (HIV-1) treatment, with particular focus on developing and evaluating novel antiretroviral regimens.
- Treatment-naïve patient therapies
- Virologically suppressed patient management
- Oral antiretroviral medications
The research encompasses both traditional daily regimens and innovative weekly dosing approaches.
Treatment Optimization
The investigator explores simplified treatment strategies for HIV management, including the evaluation of two-drug versus three-drug regimens and weekly dosing alternatives.
- Drug regimen simplification
- Fixed-dose combination therapies
- Alternative dosing schedules
Focus areas include efficacy assessment and treatment adherence optimization.
Clinical Safety Assessment
Expertise in evaluating the safety and tolerability profiles of novel HIV treatment approaches, particularly in comparing different therapeutic regimens.
- Antiviral activity assessment
- Long-term treatment outcomes
- Treatment switching strategies
The research emphasizes maintaining viral suppression while exploring alternative treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.